Brief: Atea Pharma to Present New Data Of Bemnifosbuvir For Treatment Of Covid-19 And Hepatitis C
08/03/2023 12:36
March 8 (Reuters) - Atea Pharmaceuticals Inc AVIR.O :
* NEW DATA SHOWCASING FAVORABLE PROFILE OF BEMNIFOSBUVIR FOR
TREATMENT OF COVID-19 AND HEPATITIS C TO BE PRESENTED AT 2023
INTERNATIONAL CONFERENCE ON ANTIVIRAL RESEARCH
Source text for Eikon: ID:nGNX1XF5PF
Further company coverage: AVIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atea Pharmaceuticals
See all newsAtea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline
Atea Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:30 AM